|Bid||15.80 x 800|
|Ask||16.01 x 2200|
|Day's Range||15.73 - 16.79|
|52 Week Range||4.81 - 19.43|
|Beta (5Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2021 - Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.70|
Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST.